Current Edition

consumer

For Incyte’s eczema cream Opzelura, consumer complaint reveals ongoing quality woes, replacement backlog

When Gale Wild-Ebers, 62, ordered a second tube of Incyte’s topical eczema drug Opzelura in March, something appeared wrong with the product she received. Instead …

Continue Reading →
COVID

Teva survey finds COVID has ‘widened the chasm’ on health disparities

By now, it’s no surprise that the global pandemic has worsened long-standing health inequities—and pharma has stepped up with a flood of initiatives to try …

Continue Reading →
drug development

Overview: Pharmacovigilance and Risk Management

Drug development is an expensive, lengthy, and high-risk business taking 1015 years and is associated with a high attrition rate. Approximately only 1 in 10 …

Continue Reading →
ability

New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients

Researchers from Samsung Medical Center and Guardant Health, Inc. have demonstrated the feasibility of determining a measure analogous to tumor mutation burden (TMB), a promising …

Continue Reading →
ASCO

NCI-MATCH precision medicine clinical trial releases new findings

The National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest precision medicine trial of its kind, has achieved a milestone with the …

Continue Reading →
big

In this era of personalised medicine, are big clinical trials relevant?

 The debate is surging days before the results of a large clinical trial are to be unveiled this week Sweeping clinical trials in which thousands …

Continue Reading →
Duxipient

New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma

Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad population of patients with uncontrolled …

Continue Reading →
Cornell

Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching …

Continue Reading →
bioelectronic

Bioelectronic medicine to treat lupus

Singapore – Researchers at Northwell Health’s Feinstein Institute for Medical Research are conducting a clinical trial to evaluate the efficacy of bioelectronic medicine to treat pain associated …

Continue Reading →